Observational studyKidney3602026
IgA-Producing B Cells Exert Regulatory Function through Granzyme B in Kidney Allograft Tolerance.
Observational study in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02900040 (The French DIVAT), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The French DIVAT: a Clinical Database Associated With a Biological Banking Accessible to Initiate Epidemiological and Translational Collaborative Researches in Kidney Transplantation
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
key pointsTolerant patients of kidney graft exhibit higher IgA production than other kidney transplanted patients without modification for IgG. IgA-expressing B cells from tolerant patients expressed granzyme B and exert regulatory functions through granzyme B production.
backgroundTolerant kidney transplant recipients without immunosuppression have a high frequency of circulating granzyme B (GZMB)-expressing regulatory B cells (Breg). Because the precursors of these Bregs remain unknown and IgA-secreting B cells have been shown to have regulatory properties in different situations, we investigated the association between IgA- and GZMB-expressing B cells in a case-control study.
methodsForty-five healthy volunteers and 31 kidney transplant recipients with either stable graft function under immunosuppression ( n =10), antibody-mediated rejection ( n =7), or tolerant patients (TOL; n =14) were included. Serum immunoglobulin concentrations as glycosylation were measured by ELISA; forms of IgA were examined by Western blot. Bregs were analyzed by single-cell RNA sequencing and multiparameter spectral flow cytometry. Their function was assessed in cocultured with T cells.
resultsSerum IgA concentration was elevated in TOL compared with other transplanted patients, especially the noninflammatory IgA1 subclass, without changes in IgA size or glycosylation. Single-cell transcriptomic analysis revealed higher IgA gene expression in GZMB expressing B cells and conversely higher GZMB gene expression in IgA-expressing B cells. Phenotyping analysis by spectral multiparameter flow cytometry showed that IgA+ B cells were memory B cells, and that IgA+ B cells from TOL tended to express more GZMB compared with antibody-mediated rejection patients. In functional assays, IgA+ B cells exhibited high regulatory functions that were partially prevented by the presence of GZMB inhibitor.
conclusionsThese data show a strong association between IgA+ and GZMB+ Bregs, particularly in tolerant kidney transplant recipients with higher GZMB and IgA expression and greater suppressive properties. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: NCT02900040 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.